Edgewise Therapeutics, Inc. - 8-K Filing
Edgewise Therapeutics reports Q3 2026 net income of $1.17B driven by $1.35B gain from sevasemten sale to Servier (Items: 2.02 and Item 9, 9.01 Financial Statements and Exhibits)
Tickers: $EWTX
More Regulatory news
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing
- CENTRUS ENERGY CORP - 8-K Filing
- SAGA COMMUNICATIONS INC - 8-K Filing
- NextBoat Inc. - 8-K Filing
- CIVISTA BANCSHARES, INC. - 8-K Filing